AstraZeneca is fighting to protect its biggest-selling drug, Crestor®, against generic competition. Crestor® is one of a group of heart drugs known as "statins" used to cut "bad" LDL cholesterol. Charles Lipsey, a partner at Finnegan who is representing AstraZeneca, commented that, "This drug has turned out to be quite remarkable. It's the most efficacious statin on the market in reducing bad cholesterol." Generic drugmakers filed drug applications in 2007, when the U.S. Food and Drug Administration lifted its protection on Crestor®, to begin making their own versions. But before they can proceed with manufacturing, generic drug makers must prove that Crestor'® patent is invalid: they are arguing that the patent was fraudulently obtained in the early 1990s by office workers at the Japanese company that invented Crestor® drug. Lipsey said AstraZeneca's competitors have a lot to prove during the scheduled 10-day trial, but noted that they had "chosen to attack the people, not the patent itself." He explained that the behavior of the office workers was really the result of internal disarray, rather than intentional fraud. Lipsey added that the only way Crestor® could be linked to a similar compound patented by one of AstraZeneca's competitors was "hindsight."
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Press Release
Finnegan Earns Law360’s Practice Group of the Year for Intellectual Property
January 18, 2023
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.